Signal transducer and activator of transcription 3 activation is required for Asp(816) mutant c-Kit-mediated cytokine-independent survival and proliferation in human leukemia cells.

Activating mutations of c-kit at codon 816 (Asp(816)) have been implicated in a variety of malignancies, including acute myeloid leukemia (AML). The mutant c-Kit receptor confers cytokine-independent survival of leukemia cells and induces tumorigenicity. Changes in the signal transduction pathways responsible for Asp(816) mutant c-Kit-mediated biologic effects are largely undefined. The results of this study show that Asp(816) mutant c-Kit induces constitutive activation of signal transducer and activator of transcription 3 (STAT3) and STAT1, and up-regulates STAT3 downstream targets, Bcl-x(L) and c-myc. The phosphatidylinositol-3-kinase (PI-3K)/Akt pathway, but not the Ras-mediated mitogen-activated protein (MAP) kinase pathway, is also constitutively activated by Asp(816) mutant c-Kit. Suppression of STAT3 activation by a dominant negative molecule in MO7e leukemia cells transduced with mutant c-kit inhibits stem cell factor (SCF)-independent survival and proliferation, accompanied by the down-regulation of Bcl-x(L) and c-myc. However, activated STAT3 does not appear to be the sole mediator that is responsible for the phenotypic changes induced by Asp(816) mutant c-Kit, because expression of constitutively activated STAT3 in MO7e cells does not completely reconstitute cytokine independence. Activation of other signaling components by mutant c-Kit, such as those in the PI-3K/Akt pathway, is demonstrated and may also be needed for the mutant c-Kit-mediated biologic effects. The investigation of altered signal transduction pathways and the resulting functional consequences mediated by Asp(816) mutant c-Kit should provide important information for the characterization of subsets of leukemia and potential molecular pathways for therapeutic targeting. (Blood. 2001;97:3559-3567)

[1]  R. Arceci,et al.  Activating Mutations of c-Kit at Codon 816 Confer Drug Resistance in Human Leukemia Cells , 2001, Leukemia & lymphoma.

[2]  M. Dym,et al.  Stem Cell Factor/c-kit Up-regulates Cyclin D3 and Promotes Cell Cycle Progression via the Phosphoinositide 3-Kinase/p70 S6 Kinase Pathway in Spermatogonia* , 2000, The Journal of Biological Chemistry.

[3]  E. Vellenga,et al.  Constitutive Stat3, Tyr705, and Ser727 phosphorylation in acute myeloid leukemia cells caused by the autocrine secretion of interleukin-6. , 2000, Blood.

[4]  Roy Garcia,et al.  STATs in oncogenesis , 2000, Oncogene.

[5]  J. Darnell,et al.  The role of STATs in transcriptional control and their impact on cellular function , 2000, Oncogene.

[6]  R. Jove,et al.  Activation of Stat3 preassembled with platelet-derived growth factor β receptors requires Src kinase activity , 2000, Oncogene.

[7]  Simon C Watkins,et al.  Constitutive activation of Stat3 signaling abrogates apoptosis in squamous cell carcinogenesis in vivo. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[8]  K. Manova,et al.  Point mutation in Kit receptor tyrosine kinase reveals essential roles for Kit signaling in spermatogenesis and oogenesis without affecting other Kit responses , 2000, The EMBO journal.

[9]  B. Avalos,et al.  Granulocyte colony-stimulating factor receptor mutations in severe congenital neutropenia transforming to acute myelogenous leukemia confer resistance to apoptosis and enhance cell survival. , 2000, Blood.

[10]  A. Gao,et al.  Inhibition of constitutively activated Stat3 signaling pathway suppresses growth of prostate cancer cells. , 2000, Cancer research.

[11]  F. Gouilleux,et al.  Cooperation between STAT5 and phosphatidylinositol 3-kinase in the IL-3-dependent survival of a bone marrow derived cell line , 2000, Oncogene.

[12]  T. Hunter,et al.  Kit/stem cell factor receptor-induced activation of phosphatidylinositol 3′-kinase is essential for male fertility , 2000, Nature Genetics.

[13]  P. Peterlongo,et al.  C-kit mutations in core binding factor leukemias. , 2000, Blood.

[14]  M. Jaroszeski,et al.  Gene therapy with dominant-negative Stat3 suppresses growth of the murine melanoma B16 tumor in vivo. , 1999, Cancer research.

[15]  D. Linnekin,et al.  Early signaling pathways activated by c-Kit in hematopoietic cells. , 1999, The international journal of biochemistry & cell biology.

[16]  J. Darnell,et al.  Stat3 as an Oncogene , 1999, Cell.

[17]  L. Ashman,et al.  Effects of mutant c-Kit in early myeloid cells. , 1999, Leukemia & lymphoma.

[18]  R. Jove,et al.  STAT5 activation by BCR-Abl contributes to transformation of K562 leukemia cells. , 1999, Blood.

[19]  C. Moskaluk,et al.  Activating c-kit gene mutations in human germ cell tumors. , 1999, The American journal of pathology.

[20]  M. Vignais,et al.  Distinct Mechanisms of Activation of Stat1 and Stat3 by Platelet-Derived Growth Factor Receptor in a Cell-Free System , 1999, Molecular and Cellular Biology.

[21]  D. Heitjan,et al.  Activating and dominant inactivating c-KIT catalytic domain mutations in distinct clinical forms of human mastocytosis. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[22]  T. Kaisho,et al.  Activating mutation in the catalytic domain of c-kit elicits hematopoietic transformation by receptor self-association not at the ligand-induced dimerization site. , 1999, Blood.

[23]  T. Hirano,et al.  Stat3 Is Required for the Gp130-mediated Full Activation of the C-myc Gene , 1999 .

[24]  橋本 光司.  Transforming and differentiation-inducing potential of constitutively activated c-kit mutant genes in the IC-2 murine interleukin-3-dependent mast cell line , 1999 .

[25]  J. Turkson,et al.  Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells. , 1999, Immunity.

[26]  N. Leslie,et al.  An activating mutation in the kit receptor abolishes the stroma requirement for growth of ELM erythroleukemia cells, but does not prevent their differentiation in response to erythropoietin. , 1998, Blood.

[27]  T. Hirano,et al.  STAT3 orchestrates contradictory signals in cytokine‐induced G1 to S cell‐cycle transition , 1998, The EMBO journal.

[28]  P. Besmer,et al.  Kit signaling through PI 3‐kinase and Src kinase pathways: an essential role for Rac1 and JNK activation in mast cell proliferation , 1998, The EMBO journal.

[29]  J. Grandis,et al.  Requirement of Stat3 but not Stat1 activation for epidermal growth factor receptor- mediated cell growth In vitro. , 1998, The Journal of clinical investigation.

[30]  Z. Xia,et al.  Expression of signal transducers and activators of transcription proteins in acute myeloid leukemia blasts. , 1998, Cancer research.

[31]  T. Hunter,et al.  The Kit receptor promotes cell survival via activation of PI 3-kinase and subsequent Akt-mediated phosphorylation of Bad on Ser136 , 1998, Current Biology.

[32]  A. Bressan,et al.  Highly conserved amino-acid sequence between murine STAT3 and a revised human STAT3 sequence. , 1998, Gene.

[33]  J. Darnell,et al.  Stat3 Activation Is Required for Cellular Transformation by v-src , 1998, Molecular and Cellular Biology.

[34]  J. Turkson,et al.  Stat3 Activation by Src Induces Specific Gene Regulation and Is Required for Cell Transformation , 1998, Molecular and Cellular Biology.

[35]  S. Hirota,et al.  Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. , 1998, Science.

[36]  厨子 慎一郎.  STAT3 mediates the survival signal in oncogenic ras-transfected intestinal epithelial cells , 1998 .

[37]  S. Akira,et al.  Stat3 activation is responsible for IL-6-dependent T cell proliferation through preventing apoptosis: generation and characterization of T cell-specific Stat3-deficient mice. , 1998, Journal of immunology.

[38]  L. Ashman,et al.  Expression of constitutively activated human c-Kit in Myb transformed early myeloid cells leads to factor independence, histiocytic differentiation, and tumorigenicity. , 1997, Blood.

[39]  P. Rothman,et al.  Constitutive activation of JAKs and STATs in BCR-Abl-expressing cell lines and peripheral blood cells derived from leukemic patients. , 1997, Journal of immunology.

[40]  C. Deberry,et al.  Lyn Associates with the Juxtamembrane Region of c-Kit and Is Activated by Stem Cell Factor in Hematopoietic Cell Lines and Normal Progenitor Cells* , 1997, The Journal of Biological Chemistry.

[41]  L. Schmidt,et al.  Activating mutations for the met tyrosine kinase receptor in human cancer. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[42]  C. Deberry,et al.  Stat1 associates with c-kit and is activated in response to stem cell factor. , 1997, The Biochemical journal.

[43]  T. Naoe,et al.  Internal tandem duplication of the FLT3 gene is preferentially seen in acute myeloid leukemia and myelodysplastic syndrome among various hematological malignancies. A study on a large series of patients and cell lines , 1997, Leukemia.

[44]  J. Darnell.  STATs and gene regulation. , 1997, Science.

[45]  L. Pfeffer,et al.  STAT3 as an adapter to couple phosphatidylinositol 3-kinase to the IFNAR1 chain of the type I interferon receptor. , 1997, Science.

[46]  J. Ryan,et al.  Stem cell factor activates STAT-5 DNA binding in IL-3-derived bone marrow mast cells. , 1997, Experimental hematology.

[47]  K. Penta,et al.  Distinct Signaling from Stem Cell Factor and Erythropoietin in HCD57 Cells* , 1997, The Journal of Biological Chemistry.

[48]  T Pawson,et al.  Oncogenic mutation in the Kit receptor tyrosine kinase alters substrate specificity and induces degradation of the protein tyrosine phosphatase SHP-1. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[49]  V. Gouilleux-Gruart,et al.  Constitutive activation of STAT proteins in primary lymphoid and myeloid leukemia cells and in Epstein-Barr virus (EBV)-related lymphoma cell lines. , 1996, Blood.

[50]  T. Hirano,et al.  A central role for Stat3 in IL‐6‐induced regulation of growth and differentiation in M1 leukemia cells. , 1996, The EMBO journal.

[51]  A. Gotoh,et al.  Steel factor induces serine phosphorylation of Stat3 in human growth factor-dependent myeloid cell lines. , 1996, Blood.

[52]  D. Longo,et al.  JAK2 is associated with the c-kit proto-oncogene product and is phosphorylated in response to stem cell factor. , 1996, Blood.

[53]  M. Ichihara,et al.  Signaling pathways activated in a unique mast cell line where interleukin-3 supports survival and stem cell factor is required for a proliferative response. , 1996, Blood.

[54]  A. Bernstein,et al.  A point mutation in the catalytic domain of c-kit induces growth factor independence, tumorigenicity, and differentiation of mast cells. , 1996, Blood.

[55]  M. Vignais,et al.  Platelet-derived growth factor induces phosphorylation of multiple JAK family kinases and STAT proteins , 1996, Molecular and cellular biology.

[56]  Laura H. Tang,et al.  Somatic c-KIT activating mutation in urticaria pigmentosa and aggressive mastocytosis: establishment of clonality in a human mast cell neoplasm , 1996, Nature Genetics.

[57]  B. Groner,et al.  STAT-related transcription factors are constitutively activated in peripheral blood cells from acute leukemia patients. , 1996, Blood.

[58]  Y. Suzuki,et al.  Identification of a point mutation in the catalytic domain of the protooncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[59]  H. Kitayama,et al.  Constitutively activating mutations of c-kit receptor tyrosine kinase confer factor-independent growth and tumorigenicity of factor-dependent hematopoietic cell lines. , 1995, Blood.

[60]  Y. Matsuzawa,et al.  Ligand-independent activation of c-kit receptor tyrosine kinase in a murine mastocytoma cell line P-815 generated by a point mutation. , 1994, Blood.

[61]  John J Murphy,et al.  Calcium ionophore‐induced apoptosis of human B cells is preceded by the induced expression of early response genes , 1993, European journal of immunology.

[62]  Philip,et al.  Expression of isoforms of the human receptor tyrosine kinase c-kit in leukemic cell lines and acute myeloid leukemia. , 1993, Blood.

[63]  R. Aebersold,et al.  Proteins of transcription factor ISGF-3: one gene encodes the 91-and 84-kDa ISGF-3 proteins that are activated by interferon alpha. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[64]  Alastair,et al.  Signal transduction by normal isoforms and W mutant variants of the Kit receptor tyrosine kinase. , 1991, The EMBO journal.

[65]  B. Cochran,et al.  The SIF binding element confers sis/PDGF inducibility onto the c‐fos promoter. , 1990, The EMBO journal.

[66]  P. Leder,et al.  The hematopoietic growth factor KL is encoded by the SI locus and is the ligand of the c-kit receptor, the gene product of the W locus , 1990, Cell.

[67]  David A. Williams,et al.  Stem cell factor is encoded at the SI locus of the mouse and is the ligand for the c-kit tyrosine kinase receptor , 1990, Cell.

[68]  P. Leder,et al.  The kit ligand: A cell surface molecule altered in steel mutant fibroblasts , 1990, Cell.

[69]  C. March,et al.  Identification of a ligand for the c-kit proto-oncogene , 1990, Cell.

[70]  Joseph Schlessinger,et al.  Signal transduction by receptors with tyrosine kinase activity , 1990, Cell.

[71]  G. Cattoretti,et al.  Selective growth response to IL‐3 of a human leukaemic cell line with megakaryoblastic features , 1988, British journal of haematology.

[72]  F. Ruddle,et al.  Primary structure of c‐kit: relationship with the CSF‐1/PDGF receptor kinase family–oncogenic activation of v‐kit involves deletion of extracellular domain and C terminus. , 1988, The EMBO journal.

[73]  A. Ullrich,et al.  Human proto‐oncogene c‐kit: a new cell surface receptor tyrosine kinase for an unidentified ligand. , 1987, The EMBO journal.

[74]  H. Varmus,et al.  Homogeneously staining chromosomal regions contain amplified copies of an abundantly expressed cellular oncogene (c-myc) in malignant neuroendocrine cells from a human colon carcinoma. , 1983, Proceedings of the National Academy of Sciences of the United States of America.